Zealand Falls as Sanofi Delays GLP-1 NDA; Combo Drug on Track

Shares of Zealand Pharma A/S dropped 15.4 percent last Thursday after lixisenatide partner Sanofi SA said it decided to withdraw its new drug application (NDA) for the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in Type II diabetes mellitus, with plans to resubmit in 2015 after completing a cardiovascular outcomes trial.

To continue reading subscribe now to BioWorld Asia (formerly International)